Pharmaceutical News

RSS

Aspirin may not be beneficial for young adults with diabetes

Experts are now recommending that low-dose aspirin therapy to prevent heart attacks be used somewhat more conservatively - that men younger than 50 and women younger than 60, who have diabetes but no other major risk factors, probably not use aspirin.

2 Jun 2010

Research findings advance the effort to develop AIDS vaccine

In findings that contribute to efforts to design an AIDS vaccine, a team led by Scripps Research Institute scientists has determined the structure of an immune system antibody molecule that effectively acts against most strains of human immunodeficiency virus, the virus that causes AIDS.

2 Jun 2010

Alexion Pharmaceuticals plans to launch Soliris in Japan for patients with PNH

Alexion Pharmaceuticals, Inc. and Alexion Pharma International Sàrl today announced that the launch of Soliris (eculizumab) as a treatment for patients with PNH in Japan will begin in the third quarter of 2010, approximately three months earlier than previously expected.

2 Jun 2010

LEO Pharma to find alternative solution to withdraw pharmaceutical products from Greek market

LEO Pharma is in dialogue with the Greek authorities to find an alternative solution to withdrawing the company's pharmaceutical products from the Greek market.

2 Jun 2010

Majority of poker players use performance enhancing drugs: Study

A Nova Southeastern University study recently presented at a national conference found that 80 percent of poker players around the world reported using drugs and other substances to enhance their performance in poker.

2 Jun 2010

Emerson Ecologics announces awardees of Partner status in Emerson Quality Program

Emerson Ecologics, LLC announces the debut of the first group of manufacturers to be awarded Partner status in the Emerson Quality Program(SM) (EQP). This one-of-a-kind quality assurance program for the nutritional supplements industry provides practitioners with manufacturer-specific quality and safety information to assist in confidently recommending the best products to patients.

2 Jun 2010

Anti-Dengue drug candidates demonstrate efficacy in preliminary cell culture studies

NanoViricides, Inc. reports that its anti-Dengue drug candidates demonstrated significant efficacy in the recently completed preliminary cell culture studies. The studies were performed in the laboratory of Dr. Eva Harris, Professor of Infectious Diseases at the University of California, Berkeley.

2 Jun 2010

Plans to continue flu vaccination ban – intensive investigations ongoing

In the first quarter of this year nearly 300 children across Australia fell ill with fevers, vomiting and convulsions following administration of the seasonal flu vaccine.

2 Jun 2010

Rep. Dingell opposes proposal for drug reimportation

Rep. John Dingell, D-Mich., will stand in the way of a proposal by Sen. Byron Dorgan, D-N.D., to attach a drug reimportation amendment to Dingell's food safety bill, which Dingell said "could derail the whole food safety effort," The Hill reports. "Adding to the charged politics is the widespread assumption that the Obama administration, which has made food safety a priority, may intervene behind the scenes against the amendment.

2 Jun 2010

FDA grants priority review status to Eisai's eribulin NDA

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted priority review status to the company's New Drug Application (NDA) for the investigational agent eribulin mesylate ("eribulin," also known as E7389). Eisai is seeking FDA approval for eribulin in the treatment of patients with locally advanced or metastatic breast cancer previously treated with at least two chemotherapy regimens, including an anthracycline and a taxane.

2 Jun 2010

Prototype breast cancer vaccine shows promising results in mice

US scientists have developed a prototype breast cancer vaccine that has shown promising results in very early laboratory tests on mice. The vaccine contains a protein called alpha-lactalbumin, which is found in large quantities in the majority of breast cancers.

2 Jun 2010

McGill University granted 'Orphan Drug Designation' for pulmonary infection drug fenretinide

In addition to their suffering, rare disease patients often have to face the harsh reality that few pharmaceutical companies will ever be able to offer new treatments for their condition because the costs of new treatments will never be recovered from such a small market. But there are ways they can be helped. The U.S. Food and Drug Administration's "Orphan Drug Designation" offers a wide range of benefits that help organizations developing treatments for diseases and conditions affecting fewer than 200,000 patients in the United States.

2 Jun 2010

New report shows one in three young women receive HPV vaccine to prevent cervical cancer

Only about one in three young women has received the human papillomavirus vaccine to help prevent cervical cancer, according to a new report from researchers at Washington University School of Medicine in St. Louis.

2 Jun 2010

FDA accepts Orexigen's Contrave NDA for treatment of obesity

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for Contrave® (naltrexone SR/bupropion SR), its investigational drug for the treatment of obesity.

2 Jun 2010

Over-the-counter supplements can cause hypertension and kidney failure

Negative health effects linked to taking too much supplemental calcium are on the rise, according to a commentary appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).

2 Jun 2010

Amgen's Prolia receives FDA approval for treatment of postmenopausal women with osteoporosis

Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Prolia™ (denosumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. Prolia, the first and only FDA-approved RANK Ligand inhibitor, is an every six month 60 mg subcutaneous injection administered by a health care professional.

2 Jun 2010

Teva Pharmaceutical launches Gianvi Tablets

Teva Pharmaceutical Industries Ltd. announced today that it has commercially launched Gianvi (Drospirenone and Ethinyl Estradiol) Tablets, the Company's generic version of Bayer's Yaz® Tablets.

2 Jun 2010

FDA approves Prolia for postmenopausal women with osteoporosis

The U.S. Food and Drug Administration approved Prolia, an injectable treatment for postmenopausal women with osteoporosis who are at high risk for fractures.

2 Jun 2010

CoaguSense unveils first portable point-of-care PT/INR Monitoring System for patients on oral anticoagulants

CoaguSense™, Inc., a diagnostic device company that has been in stealth mode for the past two years, today unveiled the first portable point-of-care Prothrombin Time/International Normalized Ratio (PT/INR) analyzer to directly detect blood clotting time for patients stabilized on oral anti-coagulation medications such as Coumadin® or warfarin.

2 Jun 2010

9th INT'L BIO FORUM & BIO EXPO JAPAN from June 30 - July 2, 2010

9th INT'L BIO FORUM & BIO EXPO JAPAN, organised by Reed Exhibitions Japan, will come back again as Asia's largest bio-event from June 30 - July 2, 2010. One of the hottest feature topics is "antibody drugs".

1 Jun 2010

Pharmaceutical News

Aspirin may not be beneficial for young adults with diabetes

Research findings advance the effort to develop AIDS vaccine

Alexion Pharmaceuticals plans to launch Soliris in Japan for patients with PNH

LEO Pharma to find alternative solution to withdraw pharmaceutical products from Greek market

Majority of poker players use performance enhancing drugs: Study

Emerson Ecologics announces awardees of Partner status in Emerson Quality Program

Anti-Dengue drug candidates demonstrate efficacy in preliminary cell culture studies

Plans to continue flu vaccination ban – intensive investigations ongoing

Rep. Dingell opposes proposal for drug reimportation

FDA grants priority review status to Eisai's eribulin NDA

Prototype breast cancer vaccine shows promising results in mice

McGill University granted 'Orphan Drug Designation' for pulmonary infection drug fenretinide

New report shows one in three young women receive HPV vaccine to prevent cervical cancer

FDA accepts Orexigen's Contrave NDA for treatment of obesity

Over-the-counter supplements can cause hypertension and kidney failure

Amgen's Prolia receives FDA approval for treatment of postmenopausal women with osteoporosis

Teva Pharmaceutical launches Gianvi Tablets

FDA approves Prolia for postmenopausal women with osteoporosis

CoaguSense unveils first portable point-of-care PT/INR Monitoring System for patients on oral anticoagulants

9th INT'L BIO FORUM & BIO EXPO JAPAN from June 30 - July 2, 2010

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News